Kiromic Biopharma Inc
OTC:KRBP

Watchlist Manager
Kiromic Biopharma Inc Logo
Kiromic Biopharma Inc
OTC:KRBP
Watchlist
Price: 0.0403 USD
Market Cap: $10k

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Operating
Margin
US
Kiromic Biopharma Inc
OTC:KRBP
10k USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
394.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
173.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122.4B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
88.6B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44.1B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.6B USD
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Kiromic Biopharma Inc
Glance View

Market Cap
10k USD
Industry
Biotechnology

Kiromic Biopharma, Inc. operates as a biotechnology company, which engages in the development of cancer engineered immunotherapies. The company is headquartered in Houston, Texas and currently employs 59 full-time employees. The company went IPO on 2020-10-16. The firm is focused on discovering, developing and commercializing immuno-oncology applications through its product pipeline. The company is developing a range of product candidates for the treatment of blood cancers and solid tumors. Its lead product candidates include ALEXIS-PRO-1 and ALEXIS-ISO-1. The firm is developing its brand of chimeric antigen receptor (CAR) T cell product candidates known as ALEXIS (Allogenic Lead Exogenous Isoforms). The ALEXIS platform of products has been designed to incorporate its Diamond target discovery platform into an off the shelf gamma delta T cell therapy that address the metastatic and progressive locally advanced solid malignancies, including ovarian, malignant pleural mesothelioma and multiple other indications as well. Its Diamond is a computational platform and a neural network that can identify new cancer immunological targets for T cells and B cells.

KRBP Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top